Background: The cytotoxic agent bendamustine combines a purine-like benzimidazol and alkylating nitrogen mustard group. The clinically tolerated dose for single bolus bendamustine is 215 mg/m 2 , for fractionated therapy on four consecutive days 85 mg/m 2 . The maximum tolerated dose of a day 1 and 8 (q4w) 30 min infusion schedule was recently found to be 160 mg/m 2 , mouth dryness and fatigue were dose-limiting. Our current phase I trial was designed to define the recommended dose of a new weekly short infusion schedule.
Introduction
Bendamustine (Ribomustin®, IMET-3393, Cytostasan; BM) has been developed in former German Democratic Republic in the early 1960s as a water-soluble anticancer agent [1, 2] . Among other tested nitrogen mustard derivatives, BM was selected for further preclinical and clinical development due to its good antitumour efficacy in transplantable tumour models [3] . Chemically, the agent combines a purine-like benzimidazol and an alkylating nitrogen mustard group (Figure 1) . The clinical use of BM dates back to 1969, when first objective responses were observed in patients with myeloma [4] . Since then, the drug has been successfully applied to patients with a variety of lymphoid malignancies and solid tumours. The drug is currently registered in Ger- In vitro data indicate only partial cross-resistance to agents such as cyclophosphamide, cisplatin or melphalan, and activity in doxorubicin-resistant breast cancer cell lines. The compound induces more long-lasting DNA double-strand breaks compared to other alkylating anticancer drugs [5] . After i.v. administration, BM binds to proteins such as albumin, is rapidly cleared from the plasma and hydrolyses pH-dependent to its mono-and dihydroxy-derivatives with a t 1/2 of about 10 min [6, 7] . The predominant elimination pathway is renal.
Animal toxicology studies have defined the bone marrow, the lymphatic system, the gastrointestinal and urogenital tract as potential targets for BM toxicity. The drug has immunosuppressive, embryotoxic and mutagenic properties. Known clinical side effects of BM are myelosuppression, nausea, vomiting, appetite loss, mouth dryness, taste changes, abdominal pain, sweating, flushing, allergic reactions and thrombophlebitis [8] .
Various schedules of BM are used arbitrarily with single daily doses of up to 150 mg/m 2 [9] . The manufacturer generally recommends to give either 25 mg i.v. for 14-21 days or 50-60 mg/m 2 i.v. on 3-5 consecutive days every 3-4 weeks. Most schedules of BM used in common practice have not been properly evaluated in phase I studies. Only recently, a late, more systematic pharmacological evaluation of the compound has been initiated, including preclinical investigations and clinical phase I-III trials, mainly focusing on the use of BM in lymphoid tumours and breast cancer. Our recent phase I-study evaluated the maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and recommended dose (RD) of BM given as a 30 min i.v. infusion on days 1 and 8 of a four-week treatment cycle [10] . We recommended a dose of 140 mg/m 2 for this specific schedule. Fatigue and mouth dryness were dose limiting and we observed a high incidence of lymphocytopenia.
The weekly administration of chemotherapeutic agents has recently attracted a number of clinical investigators. Some drugs were found to be better tolerated and achieved considerable dose-intensity when given on a weekly basis. Due to the preferable toxicity profile, weekly chemotherapy is currently used as the basis for a number of innovative drug combinations. Alkylating agents are not known to be very schedule dependent, unless there are marked non-myelosuppressive dose limiting effects which make fractionation necessary. In our previous trial we did observe that BM does have doselimiting non-haematological toxicity when given as a 30-min i.v. infusion. Considering the experience of other investigators, both the infusion duration and dose fractionation appear to affect the toxicity profile of this antineoplastic drug. We were thus interested in providing safety data and to determine the MTD and RD for weekly single-agent BM given over 30-min i.v. Furthermore, we wanted to elucidate effects of the compound on various lymphocyte subsets using flow cytometry.
Patients and methods

Eligibility
Patients with histologically proven malignant solid tumours refractory to conventional treatment qualified for the trial, if they were > 18 years old, had a life expectancy of > 3 months, a WHO Performance Status of 0-2, a haemoglobin value > 9.0 g/dl, a white blood count ^ 4000/ ul and platelets 3s 100.000/ul. Patients were excluded in case their serum GOT, bilirubin, alkaline phosphatase, creatinine or urea nitrogen levels were > 2 times above the upper normal limit, or in case of severe concomitant disease such as congestive heart failure, peptic ulcer or acute infections. The study was approved by the local ethics committee. Written informed consent was obtained from the participating patients.
Treatment
The study drug was supplied by ribosepharm GmbH (Munich. Germany) in sterile vials containing 100 mg BM-hydrochloride. to be administered in 500 ml sodium chloride 0.9% over 30 minutes as a peripheral or central i.v. infusion. The time of drug administration via electronic pumps was standardised to 10.00-10.30 a.m. The treatment was given on an outpatient basis.
BM was administered weekly for up to eight weeks. The patients were allowed to continue without rest after that if they did respond to the treatment. The starting dose was defined as 80 mg/m 2 , based on previous experience of the weekly administration of BM at this dose in a number of individual patients outside of clinical trials. Our recent phase I study had shown that doses of 280-360 mg/m 2 could be administered over a period of four weeks with fractionated dosing [10] . A dose of 85 mg/m 2 was found to be tolerable when given over four consecutive days as a 3 min i.v. short infusion (ribosepharm, data on file). A significant dose escalation was not anticipated, but the protocol provided a dose-increment schedule in case the starting dose of the weekly schedule was well tolerated. Groups consisted of at least three patients. The group-wise dose-escalation was to be continued until DLT was observed.
DLT was defined as any non-haematological grade 4 toxicity according to the NCI-Common Toxicity Criteria version 1.0 (CTC), any life-threatening grade 3 event, or any combination of grade 3 nonhaematological toxicities occurring per cycle (8 weeks). Leukocytopenia <1500/ul or thrombocytopenia <50,000/ul lasting for more than 14 days, and leukopenia < 1000/ul or granulocytopenia < 500/ul of more than 5 days duration were also regarded dose-limiting Nausea, vomiting and lymphocytopenia were not defined as DLT, if not associated with a life-threatening event. If one patient had a doselimiting event, three further individuals had to be treated on that dose level before the next escalation step was considered. Patients with DLT were taken off study. MTD was defined as the dose level on which two or more patients had a DLT. In case the chosen starting dose was doselimiting, the next dose level to be investigated according to protocol was 60 mg/m 2 . The RD for further trials was defined as one dose level below MTD (MTD minus 20 mg/m 2 ) At least six patients had to be treated with this dose. An intraindividual dose-escalation was not permitted. Ethics committee approval was obtained to treat another three patients at an intermediate dose of 70 mg/m 2 to further study drug safety in younger, less heavily pre-treated individuals. Supportive care was at the discretion of the physicians involved, the concomitant use of other cytotoxic or experimental agents was prohibited, haematopoietic growth factors were not given.
Assessment of toxicity and response
Haematological and non-haematological toxicity was assessed according to the NCI-CTC. The evaluation of side effects was based on weekly outpatient visits. The following investigations were done at baseline, every four weeks on study and at the end of treatment: physical examination, toxicity assessment, vital signs, blood sedimentation rate, coagulation parameters, differential blood count, serum analysis including sodium, potassium, calcium, magnesium, phosphate, creatinine, blood urea nitrogen, uric acid, GOT, GPT, GLDH, alkaline phosphatase, yGX cholinesterase, lactate dehydrogenase, creatinine kinase, bilirubin, protein, albumin, c-reactive protein, glucose, creatinine clearance, urine status and sediment. On a weekly basis, we did a physical examination, toxicity assessment, vital signs, coagulation parameters, differential blood count, urine status and all serum parameters listed above For assessment of potential cardiac toxicity, electrocardiograms were done on days 1, 8, 29 and 57, and the left ventricular ejection fraction was studied by technetium scan at baseline and after the end of treatment.
The maximum haematological and non-haematological toxicity per patient during the first treatment cycle was documented with grade, severity, duration and a causality assessment. For the final determination of DLT, MTD and RD, only events were taken into account, which were either unexplained or causally related to the use of BM and unrelated to the tumour or co-morbidity.
In patients with measurable disease, response was assessed according to WHO criteria, the reevaluation was done every eight weeks.
Immunophenotyping
Heparinised blood samples were collected at baseline and on days 8, 29 and 57 of treatment. Aliquots of 100 ul each were incubated with fluorescent monoclonal antibodies (Becton Dickinson, Heidelberg, Germany: Beckman/Coulter: Krefeld. Germany) targeted against CD2, CD3, CD4. CD8. CD14. CD16. CD19. CD20. CD38. CD45. 
«_7
-/ fluororescein isothiocyanate and phytoerithricin. The samples were treated for 10 mm at 20 °C with Optilyse® (Beckman/Coulter, Krefeld), incubated with antibody for 15 min and centrifuged twice at 1000 U/min for 10 min. For flow cytometric analysis (Coulter EPICS® XL-MCL, Hileah, USA), the samples were resuspended with 0.5 ml PBS buffer. Lymphocytes were detected by forward-and side scatter signals, 10000 cells were acquired per sample. Appropriate isotype controls were used to set up amplification and compensation of the flow cytometer. The lymphocyte gate was determined based on CD45/ CD14 expression. Two-parametric dot plots ware used to determine the absolute count of lymphocytes with B-, T-or NIC-cell phenotype and activated lymphocytes.
Statistical analysis
For interpretation of the clinical data only descriptive statistics were applied. Results in tables and figures are presented either in absolute numbers, group mean values with standard error or median with range as indicated. The Friedmann test was used for comparing lymphocyte subset counts during the course of treatment.
Results
Between March and November 1999, eight male and four female patients entered the trial. The main characteristics of this patient population are presented in Table 1 . Colorectal cancer was the most frequent disease. The patients were pre-treated with up to five different chemotherapy regimen, no patient had been exposed to BM prior to study entry. All had refractory disease, only two partial responses had been documented in 30 previously administered regimens. In contrast to other typical phase I study populations, only a minority of Three patients were treated at the dose level 80 mg/m 2 , six patients received 60 mg/m 2 . Three further patients were treated with an intermediate dose of 70 mg/m 2 . The absolute dose delivered was ranging from 99-144 mg/week. Sixty-seven weekly infusions were administered. The median number of infusions per patient was 6.5 (range 1-8). All patients received the full projected dose, dose reductions were not done. Only two drug administrations were delayed for seven days due to nonhaematological toxicity (upper airway infections). No treatment was delayed for haematological events.
Toxicity
The maximum haematological and non-haematological toxicity per patient is shown in Tables 2 and 3 . Anaemia was pre-existing in two patients, two blood transfusions had to be given during the course of treatment. Thrombocytopenia was clinically irrelevant. Leukopenia was infrequent and generally mild, only one patient had leukopenia grade 3 and granulocytopenia 2. The observed decrease in the white blood count was in part explained by grade 3-4 lymphocytopenia. Lymphocyte nadirs of 100-300/ul occurred on all dose levels of BM. Opportunistic infections were not observed.
A variety of non-haematological side effects were documented on all tested dose levels. Mouth dryness, fatigue, nausea, diarrhoea, vomiting and appetite loss were the most common observations. No changes over time were observed for the left ventricular ejection fraction, no peripheral neurotoxicity was seen (data not Other toxicities such as fever or arrhythmia occurred in < 20% of the patients.
shown). Only one patient was hospitalised for BMrelated toxicity (arrhythmia, see below), no toxic deaths occurred.
Dose-limiting events, maximum tolerated and recommended dose
DLT as defined in the protocol did occur in two out of three patients treated at the 80 mg/m 2 starting dose level. One patient who received a total number of 4 infusions had fatigue grade 3 and fever grade 4. One patient had fatigue grade 3 and dryness of mouth grade 3 after four weekly administrations of BM. According to the protocol, 80 mg/m 2 was regarded dose-limiting and the dose for the next group of patients was decreased to 60 mg/m 2 . A total number of six patients were treated with this dose. Forty weekly infusions were given. The most common side effects at RD were dryness of mouth, lymphopenia, nausea and fatigue. One patient with head and neck cancer and a past medical history of intermittent tachycardia and arterial hypertension had a dose-limiting, possibly drug-related event after receiving a total number of four infusions of BM 60 mg/m 2 . He had to be admitted for vertigo, tachycardia and arrhythmia. The electrocardiogram revealed atrial flutter with 2 :1 conduction as the underlying condition. Treat- ment with Verapamil appeared ineffective, but the patient converted spontaneously to a regular sinus rhythm during electrophysiologic examination. His electrocardiogram and left ventricular ejection fraction at study entry were unremarkable. The patient was not re-exposed to BM for safety reasons and developed CNS involvement of his malignant disease within one week after termination of the treatment. No further DLT occurred at the 60 mg/m 2 dose level, which was defined as RD according to protocol.
The intermediate dose level of 70 mg/m 2 was studied in three additional patients. It was not associated with DLT and had a toxicity profile very similar to that of the RD in selected, less heavily pre-treated patients.
Response assessment and reasons for treatment discontinuation
No objective responses were achieved in these patients with refractory malignancies. One patient with locally advanced pancreatic adenocarcinoma not responding to both gemcitabine and folinic acid/infusional high-dose 5-fluorouracil had a short-term 62% decrease of the tumour marker CA 19.9 as compared to baseline. Reasons for treatment discontinuation in this phase I trial were disease progression (6 patients), non-haematological toxicity (3), death due to pulmonary embolism (1) and refusal for personal reasons (2) .
Lymphocyte toxicity
The absolute lymphocyte count during the course of treatment is illustrated in Figure 2 , the relative decrease in B-,T-, NK-cells and activated lymphocytes compared to baseline is shown in Figure 3 . According to flow cytometry, BM induced panlymphopenia with a > 90% decrease in peripheral blood B-cells, > 70% decrease in NK-cells and >60% decrease in T cells after four weekly administrations. The observed differences over time (day 1 vs. day 29) in eight fully evaluable patients were statistically significant for CD2, CD 3, CD 4, CD8, CD14, CD16, CD19, CD20, CD38, CD45, CD56, CD57 and HLA DR (P < 0.05, Friedmann test). The T4/8-ratio remained constant during the whole treatment period.
Discussion
Since having been developed as a nitrogen mustard derivative in the early 1960s, BM has shown considerable antineoplastic activity in animal models and good efficacy in patients with lymphoid tumours and other malignancies. The dose and schedule of BM used in common practice and in published clinical trials is arbitrary, since only a very limited number of valid phase I studies have been fully published yet. We recently provided a MTD, DLT and RD for 30 min iv. infusions of BM on days 1 and 8 of four-week treatment cycle, to support an ongoing phase III investigation with the compound in patients with breast cancer [10] .
A previous, not fully published clinical observation involved step-wise dose-escalations for BM in cancer patients [11] . The agent was given as a single i.v. bolus, with relative doses ranging from 54-226 mg/m 2 . Based on the toxicity observed at the highest doses, a clinically tolerated dose of about 215 mg/m 2 was defined. Confusion and lethargy did occur, mouth dryness and taste changes were regarded dose-limiting. Cardiovascular events with chest pain, arrhythmia, palpitations, sweating and fear were observed but appeared responsive to vasodilating agents. In patients exposed to 3-min i.v. infusion of BM over four consecutive days, relative single doses ranged from 20-88 mg/m 2 per day, leukopenia and thrombocytopenia were dose-limiting at about 85 mg/m 2 (ribosepharm, data on file). In accordance with our previous phase I data, the weekly 30-min infusion of BM in our current trial was associated with non-haematological DLT such as mouth dryness and fatigue and we also documented some sporadic evidence of cardiac toxicity at recommended dose. Salivary gland dysfunction and taste changes are well-known side effects of nitrogen mustard derivatives. Fatigue and lethargy are increasingly observed as relevant side effects of cancer treatment, but are still very difficult to assess properly in clinical trials. Mild cardiac arrhythmia has been reported in up to 16% of patients exposed to BM [12] . We did not observe confusion or other signs of neurotoxicity when giving the drug as a repeated 30-min i.v. infusion.
Confirming our previous results with the day 1 and 8 schedule, leukopenia and thrombocytopenia were not dose-limiting with the weekly regimen. Interestingly, haematological toxicity was observed more frequently in other clinical trials [9, 12] . Only a minority of our patients had been exposed to extensive radiotherapy or anticancer agents inducing severe and persistent myelotoxicity, and our phase I population had malignancies characterised by a very low incidence of bone marrow involvement.
An observation of our previous trial was the high incidence and grade of lymphocytopenia. It is known that the drug is capable of inducing reversible blood B and T lymphocytopenias, and both CD4-and CD8-positive cells may be affected. The induction of lymphocyte toxicity is a pharmacological rationale for the treatment of lymphoid malignancies and autoimmune diseases with BM and a reason for the good efficacy of the agent in some haematological diseases [13] . In the treatment of solid tumours such as breast cancer [9, 14, 15] , however, a different mode of action takes effect. Little is known about the selective action of the agent on different lymphocyte subsets. For this reason we incorporated immunophenotyping of peripheral blood lymphocytes in this prospective trial. BM was found to affect all types of lymphocytes, including B-, T-and natural killer cells. B cells appeared to be most sensitive for BM toxicity with a > 90% decrease in peripheral blood counts after four weeks of treatment. One could argue that these findings suggest an increased risk of opportunistic infections when treating solid tumours with BM. This hypothesis, however, is not supported by the current experience and safety data from other clinical studies with this agent.
Our phase I data provide a good reference for the use of BM as a 30-min i.v. infusion in future trials. We recommend a dose of 60 mg/m 2 for the weekly administration of the alkylating agent, which could possibly be increased to 70 mg/m 2 in selected patients. Combinations of the weekly schedule with other antineoplastic agents with non-overlapping toxicity profiles should be considered for further clinical evaluation in sensitive tumour types.
